追求乙型肝炎临床治愈的适合人群与策略

doi:10.3969/j.issn.1672-5069.2019.03.002

实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (3): 309-312.doi: 10.3969/j.issn.1672-5069.2019.03.002

追求乙型肝炎临床治愈的适合人群与策略

王晓晓, 陈新月

100069 北京市首都医科大学附属北京佑安医院国际医疗部

收稿日期:2019-02-27 出版日期:2019-05-10 发布日期:2019-05-15
通讯作者: 陈新月,E-mail：Chenxydoc@163.com
作者简介:王晓晓,女,25岁。E-mail：wxxdoc@163.com
基金资助:
*“十三五”国家科技重大专项课题（编号：2017ZX10202201/2017ZX10201021-001-008/2017ZX10302201）; 首都临床特色应用研究与成果推广项目（编号：Z161100000516018/Z151100004015181）; 首都卫生发展科研专题项目（编号：首发2016-1-2183）

Therapeutic strategy for serum HBsAg clearance in suitable population of chronic hepatitis B

Wang Xiaoxiao, Chen Xinyue

International Medical Cantre,You'an Hospital,Affiliated to Capital Medical University,Beijing 100069zhaiiyao

Received:2019-02-27 Online:2019-05-10 Published:2019-05-15

摘要/Abstract

关键词: 慢性乙型肝炎, HBsAg清除, 适合人群, 治疗策略, 长效干扰素

Key words: Hepatitis B, HBsAg clearance, Suitable population, Treatment strategy, Pegylated interferon-α

王晓晓, 陈新月. 追求乙型肝炎临床治愈的适合人群与策略[J]. 实用肝脏病杂志, 2019, 22(3): 309-312.

Wang Xiaoxiao, Chen Xinyue. Therapeutic strategy for serum HBsAg clearance in suitable population of chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 309-312.

[1] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol,2017,67(2):370-398.
[2] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ.
[3] Sarin SK,Kumar M,Lau GK,et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update. Hepatol Int,2016,10(1):1-98.
[4] Terrault NA,Bzowej NH,Chang KM,et al.AASLD guidelines for treatment of chronic hepatitis B. Hepatology,2016,63(1):261-283.
[5] Liang Y,Jiang J,Su M,et al.Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther,2011,34(3):344-352.
[6] Chen CH,Lu SN,Hung CH, et al.The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol,2014,61(3):515-522.
[7] Liu J,Li T,Zhang L,et al. The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among Asian chronic hepatitis B patients:a systematic review. Hepatology,2018[ahead of print].
[8] Rang A,Bruns M,Heise T,et al.Antiviral activity of interferon-alpha against hepatitis B virus can be studied in non-hepatic cells and Is independent of MxA. J Biol Chem,2002,277(10):7645-7647.
[9] Ning Q,Han M,Sun Y,et al.Switching from entecavir to peg IFN alfa-2a in patients with HBeAg-positive chronic hepatitis B:a rando mised open-label trial (OSST trial). J Hepatol,2014,61(4):777-784.
[10] Lau GK,Piratvisuth T,Luo KX,et al.Peginterferon alfa-2a, lamivudine,and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med,2005,352(26):2682-2695.
[11] Kim GA,Lim YS,An J,et al.HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B:clinical outcomes and durability. Gut,2014,63(8):1325-1332.
[12] Hu P,Shang J,Zhang W,et al.HBsAg loss with peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog:New Switch Study. J Clin Transl Hapatol,2018,6(1):25-34.
[13] Lampertico P,Vigano M,Di Costanzo GG,et al.Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut,2013,62(2):290-298.
[14] Xie Q,Cai W,Ouyang LJ,et al. Effectiveness of response-guided peginterferon alfa-2a therapy in nucleos(t)ide analogues treated patients with Hbeag-positive chronic hepatitis B:interim analysis of a prospective,multicenter,randomized study. Hepatology,2018[ahead of print].
[15] Chen JD,Yang HI,IIoeje UH,et al.Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology,2010,138(5):1747-1754.
[16] McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology,2009,49(5S):S45-55.
[17] Cao Z,Liu Y,Ma L,et al.A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. Hepatology,2017,66(4):1058-1066.
[18] Li MH,Xie Y,Zhang L,et al.Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a. World J Hepatol,2016,8(15):637-643.
[19] 闫一杰,王晓晓,曹振环,等. 48周HBsAg低水平的HBeAg阴性慢性乙型肝炎患者是获得HBsAg清除的优势人群. 中华肝脏病杂志,2018,26(11):813-818.

追求乙型肝炎临床治愈的适合人群与策略

Therapeutic strategy for serum HBsAg clearance in suitable population of chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[6]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[7]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[8]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[9]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[10]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[11]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.
[12]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[13]	闫瑞斌, 马淑梅, 卓玛, 乔志忠, 刘潇. 慢性乙型肝炎患者血清MMP-2和TIMP-2水平及超声检查指标评估肝纤维化分期意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 506-509.
[14]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.
[15]	彭思璐, 刘冰, 孙宏, 林剑, 潘志颖, 邓存良. HBV相关慢加急性肝衰竭患者预后及其影响因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 545-548.